Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays

Clinical Chemistry

Volumn 57, Issue 4, 2011, Pages 555-559

  Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ESTROGEN; GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; HUMAN GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

ACCURACY; ACROMEGALY; ANTIBODY SPECIFICITY; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD SAMPLING; BODY MASS; CHRONIC KIDNEY FAILURE; CONSENSUS DEVELOPMENT; GEL CHROMATOGRAPHY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL SOCIETY; PEPTIDE ANALYSIS; PREGNANCY; PROTEIN BINDING; PROTEIN DETERMINATION; PUBERTY; STANDARDIZATION;

ANTIBODY SPECIFICITY; CLINICAL CHEMISTRY TESTS; GROWTH HORMONE; HUMANS; REFERENCE STANDARDS; SOMATOMEDINS;

EID: 79956157928     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.150631     Document Type: Article

References (28)

1. LeRoith D, Yakar S. Mechanisms of disease. Metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007;3:302-10.
2. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007;6: 821-33. (Pubitemid 47500506)
3. Ho KKY, on behalf of the 2007 GH Deficiency Consensus Workshop participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007;157: 695-700.
4. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman L, Grossman A, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054-8.
5. Giustina A, Barkan A, Channson P, Grossman A, Hoffman A, Ghigo E, et al. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 2008;31:820-38.
6. Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays - a 2009 update. Growth Horm IGF Res 2009;20:8-18.
7. Bidlingmaier M, Freda PU. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm IGF Res 2009;20:19-25.
8. Seth J, Ellis A, Al-Sadie R. Serum growth hormone measurements in clinical practice: an audit of performance from the UK National External Quality Assessment scheme. Horm Res 1999;51:13-9. (Pubitemid 29301278)
9. Morsky P, Tiikkainen U, Ruokonen A, Markkanen H. Problematic determination of serum growth hormone: experience from external quality assurance surveys 1998-2003. Scand J Clin Lab Invest 2005;65:377-86.
10. Trainer PJ, Barth J, Sturgeon C, Wieringaon G. Consensus statement on the standardisation of GH assays. Eur J Endocrinol 2006;155:1-2. (Pubitemid 44103367)
11. Tanaka T, Tachibana K, Shimatsu A, Katsumata N, Tsushima T, Hizuka N, et al. A nationwide attempt to standardize growth hormone assays. Horm Res 2005;64(Suppl 2):6-11. (Pubitemid 41665850)
12. Quarmby V, Quan C. How much insulin-like growth factor (IGF-I) circulates?: impact of standardization on IGF-I assay accuracy. Dev Biol Stand 1999;97:111-8.
13. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 1991;12:424-49.
14. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa JE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 2007; 67:65-70. (Pubitemid 46955441)
15. Ebdrup L, Fisker S, Sorensen HH, Ranke MB, Ørskov H. Variety in growth hormone determinations due to use of different immunoassays and to the interference of growth hormone-binding protein. Horm Res 1999;51:20-6.
16. Derr RL, Cameron SJ, Golden SH. Pre-analytic considerations for the proper assessment of hormones of the hypothalamic-pituitary axis in epidemiological research. Eur J Epidemiol 2006;21: 217-26.
17. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML, Stephens PA. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006; 91:1621-34.
18. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 2000; 85:3990-3.
19. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9. (Pubitemid 32273628)
20. Bristow AF, Jespersen AM. The Second International Standard for somatropin (recombinant DNA-derived human growth hormone): preparation and calibration in an international collaborative study. Biologicals 2001;29:97-106. (Pubitemid 32977038)
21. Sturgeon C, Ellis AR, Al-Sadie R. UK NEQAS for peptide hormones: annual review for 2009. Edinburgh (UK): National External Quality Assessment Service; 2010. p 22-6.
22. Miller WG, Myers GL, Rej R. Why commutability matters. Clin Chem 2006;52:553-4.
23. Jan T, Shaw MA, Baumann G. Effects of growth hormone-binding proteins on serum growth hormone measurements. J Clin Endocrinol Metab 1991;72:387-91. (Pubitemid 21921704)
24. Popii V, Baumann G. Laboratory measurements of growth hormone. Clin Chim Acta 2004;350:1-16.
25. Burns C, Rigsby P, Moore M, Rafferty B. The First International Standard for Insulin-like Growth Factor-I (IGF-I) for immunoassay: preparation and calibration in an international collaborative study. Growth Horm IGF Res 2009;19:457-62.
26. Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, et al. Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 2004;89: 2271-4. (Pubitemid 38619863)
27. Clemmons DR. IGF-I assays: current assay methodologies and their limitations. Pituitary 2007;10: 121-8. (Pubitemid 46863726)
28. CLSI (formerly NCCLS). Defining, establishing and verifying reference intervals in the clinical laboratory: approved guidelines - third edition. CLSI document C28A3E. Wayne (PA): CLSI; 2008.